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mRNA turnoverTo serve as templates for translation eukaryotic mRNAs undergo an elaborate processing and
maturation pathway. In eukaryotes this process comprises the synthesis of mRNA precursors, their
processing and transport to the site of translation and eventually their decay. During the entire life
cycle, mRNAs interact with distinct sets of trans-acting factors that determine their fate at any given
phase of gene expression. Recent studies have shown that mutations in components acting in trans
on mRNAs are frequent causes of a large variety of different human disorders. The etiology of most
of these diseases is, however, only poorly understood, mostly because the consequences for
mRNA-metabolism are unclear. Here we discuss three prominent genetic diseases that fall into this
category, namely spinal muscular atrophy (SMA), retinitis pigmentosa (RP) and X-linked syndromic
mental retardation (XLMR). Whereas SMA and RP can be directly linked to mRNA processing, XLMR
results from mutations in the mRNA surveillance system. We discuss how defects in mRNA matura-
tion and turnover might lead to the tissue speciﬁc defects seen in these diseases.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The maturation of protein coding messenger RNA (mRNA) and
its commitment to translation are key events in gene expression.
While mRNA was long considered a rather passive carrier of infor-
mation, it became increasingly clear in recent years that it is also
central to a variety of post-transcriptional gene regulatory mecha-
nisms. These mechanisms affect almost all steps in the life cycle of
an mRNA and involve the formation, modiﬁcation and degradation
of mRNA-protein complexes (mRNPs) [1]. The starting point of
mRNP production in eukaryotes is the generation of a precursor
mRNA (pre-mRNA) by RNA polymerase II (RNAP II), which is then
processed to reach maturity. Processing events include capping of
the 50 end [2], typically pre-mRNA splicing to remove non-coding
introns [3], and the generation of a 30 end by cleavage and
polyadenylation [4]. Proper maturation of mRNA in the nucleus
is a prerequisite for its subsequent export to the cytosol and deter-
mines its subcellular localization as well as its ability to associate
with the translation machinery. In the course of this pathway,
the mRNA attracts and ejects the trans-acting factors that make
up the mRNP and are crucial for the respective phase (Fig. 1).The initial association of proteins with mRNAs occurs as soon as
the 50-end of a nascent transcript emerges from RNAP II (Fig. 1).
Many of the factors that are connected to its processing and the
subsequent nuclear export associate with the mRNA in this initial
phase [5]. These include the capping and polyadenylation machin-
ery, the spliceosome and cleavage and polyadenylation factors, all
of which are co-transcriptionally recruited onto mRNA [6]. As part
of nuclear processing, not only the RNA-structure is altered but
also its association with proteins [5]. This process, which is
referred to as mRNP remodeling, licenses the mRNP for nuclear
export [7]. Important marks of this licensing process are the
splicing-dependent deposition of exon junction complexes (EJCs)
and the recruitment of mRNA export factors such as the metazoan
transcription-export (TREX) complex [8,9]. Remodeling continues
in the cytosol where some mRNAs associate with transport factors
that establish the subcellular localization that is required for their
functionality [10]. Translation of mRNPs by ribosomes leads to fur-
ther remodeling, for example the replacement of the nuclear cap
binding complex by eIF4E and the disassembly of the EJCs [11,12].
As already implied from the above said, mRNAs interact at all
stages of their life with distinct sets of trans-acting factors (mostly
proteins but also small RNAs, RNPs and metabolites) to form
mRNPs. This ‘‘mRNP code’’ determines the fate of any given
mRNA and is thus the major denominator of processing and
post-transcriptional gene regulation. Perhaps not surprisingly,
Fig. 1. Assembly and remodeling of mRNPs in the nucleus and cytoplasm. An initial set of RNA-binding proteins associates with the mRNA during transcription by RNA
polymerase II. Early mRNP components include hnRNP proteins and the mRNA processing machinery, for example the snRNPs of the spliceosome. The composition of the
mRNP is altered during different gene expression steps and actively inﬂuences its fate. After transport to the cytoplasm the mRNA is translated and eventually degraded.
Important components of the mRNP are depicted.
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RNA-binding proteins, their mRNA binding sites or their recruit-
ment and remodeling factors are increasingly recognized as causes
of human disease. This includes a variety of non-neurological dis-
orders like oculopharyngeal muscular dystrophy [13], hypotri-
chosis simplex [14], and various forms of cancer but is especially
prominent in the etiology of neuronal disease. Examples include
amyotrophic lateral sclerosis (ALS), which can be caused by defects
in RNA-binding proteins [15] as well as toxic RNA trinucleotide
repeat expansions [16,17], Fragile X Syndrome (FXS), which is
caused by mutations in the FMR1 gene that encodes a key regula-
tor of neuronal mRNA translation [18], and spinocerebellar ataxia
which is also often caused by trinucleotide repeat expansions
[19]. Here, we focus on diseases that are directly linked to mRNA
processing and mRNP remodeling and summarize recent progress
that has been made in the understanding of the disorders spinal
muscular atrophy (SMA), retinitis pigmentosa (RP) and X-linked
syndromic mental retardation (XLMR). These diseases are caused
by defects in the assembly of the spliceosomal machinery, the
function of the spliceosome itself and the mRNA surveillance path-
way, respectively.2. Spinal muscular atrophy: defects in the formation of the
splicing machinery
SMA is a prime example of a disease linked to the
general pre-mRNA splicing machinery. The degeneration of
a-motoneurons in the spinal cord is the main cellular characteristic
of this common autosomal recessive disorder. Compound heterozy-
gous mutations or deletions of the SMN1 gene copy, which prevent
the expression of functional SMN protein, are the sole cause of this
disease [20]. Humans contain one or several copies of a second
SMN-gene (termed SMN2). Even though both genes potentially
encode for the same protein, a single nucleotide C to T transition
in exon 7 results in mis-splicing of the majority of the SMN2
encoded pre-mRNA [21–23]. This results in the production of a
truncated protein from SMN2, which is unstable and non-functional
(Fig. 2). SMA therefore results from SMN-deﬁciency, and the deletion
of the SMN1 gene cannot be fully compensated by SMN2. There are
no SMApatients known that completely lack SMN and the complete
knockout of SMN in various model organisms such as mice,
Caenorhabditis elegans and Schizosaccharomyces pombe is lethal,
suggesting that SMN fulﬁlls an essential function [24].
Fig. 2. Spinal Muscular Atrophy is caused by reduced expression of the snRNP
assembly factor SMN. (upper panel) Humans have two SMN genes (SMN1 and
SMN2). SMN1 produces full-length and functional SMN protein whereas SMN2
produces predominantly a truncated and non-functional version (SMNDExon7,
left). Due to mutations in the SMN1 gene only very low levels of SMN protein are
produced in SMA patients (right). (lower panel) The SMN protein is part of an
intricate system that ensures the assembly of spliceosomal snRNPs. The SMN
complex consists of SMN as well as the proteins Gemins2–8 (denoted 2–8 in the
ﬁgure) and unrip. The Sm proteins (termed B, D1, D2, D3, E, F and G) are recruited to
the SMN complex and loaded onto the snRNA.
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processing spliceosome. This dynamic macromolecular complex
catalyses the excision of non-coding sequences (introns) from
pre-mRNAs thereby generating the open reading frame for transla-
tion. The major spliceosome, which splices the vast majority of
pre-mRNAs is composed of a group of RNA-protein complexes ter-
med small nuclear ribonucleoproteins (snRNPs) U1, U2, U4/6 and
U5 as well as a large number of additional proteins. Cells possess
also a ‘‘minor’’ spliceosome, which splices rare non-canonical
(minor) introns found in some pre-mRNAs [25]. Even though some
components of this machinery differ, their overall biochemical
composition is very similar to the major spliceosome and includes
homologous U snRNPs (termed U11, U12, U4atac and U6atac
snRNPs) and associated splicing factors.
A large body of evidence has implicated SMN in the assembly of
the Sm-class of U snRNPs and hence also the formation of the func-
tional major and minor spliceosomes. The Sm-class of U snRNPs
are assembled in cells in a complex and segmented biogenesis
pathway. This pathway starts with the transcription of the
snRNA by polymerase II and its subsequent nuclear export to the
cytoplasm. The U snRNA then binds to a set of common (Sm) pro-
teins that form the core RNA of these particles as well as additional
speciﬁc U snRNP factors. After additional maturation steps, includ-
ing the hypermethylation of the m7G-cap to the m3G-cap the
assembled snRNP particle is imported into the nucleus and eventu-
ally incorporated into the spliceosome [26–28].
The best-understood role of SMN in the biogenesis cycle is the
cytosolic assembly of the common Sm proteins with the snRNA
and the subsequent nuclear import and maturation to fully func-
tional particles [29] (Fig. 2). The SMN protein acts in the context
of a macromolecular unit, which also contains 7 proteins collec-
tively referred to as ‘‘Gemins’’ as well as the factor unrip. This
so-called SMN complex ensures the efﬁcient loading of Sm proteins
onto the U snRNP and hence the formation of the RNP core of these
particles [30–33]. As this core is important for the subsequent
nuclear import and incorporation into spliceosomes, SMN (andthe entire SMN-complex) can be considered to be of major impor-
tance for the splicing machinery in general.
Whether the disease SMA is a direct consequence of perturba-
tions in the U snRNP biogenesis pathway or downstream events
thereof such as splicing is an intriguing albeit still controversially
discussed question. What appears undisputed is that SMN deﬁ-
ciency provokes a marked reduction of assembly activity and U
snRNP levels in most cells tested so far, including neuronal cells
derived from animal models of SMA. Of note, the formation of
snRNPs of the minor spliceosomes appears to be more affected
than snRNPs of major spliceosomes [34–37]. The downstream con-
sequence of cellular U snRNP shortage is, however, less clear. In
agreement with the disturbance of pre-mRNA processing, massive
alterations in the splicing pattern of a variety of different mRNAs
were observed in animal models such as mice, ﬂies and even yeast.
Consistent with a pronounced reduction of the minor snRNPs bio-
genesis, mRNAs containing minor introns are frequent among the
mis-spliced transcripts [37–41]. Whether these alterations directly
result from SMN deﬁciency or whether they are secondary to
cell/tissue degeneration needs to be sorted out by further studies
that include the analysis of animal models at time points prior to
disease onset. It is presently disputed whether these mis-splicing
events are causative for the disease [42]. In favor of this view, a
mis-spliced transcript containing a minor intron has been identi-
ﬁed in a Drosophila melanogaster model of SMA. As the encoded
protein, termed Stasimon is required for motor circuit function,
this ﬁnding provided an explanation for the tissue speciﬁcity of
the disease [43,44]. On the other hand, the investigation of
age-matched Smn-null and Smn ﬂies by a deep sequencing
approach failed to detect altered expression of mRNAs containing
minor introns [44]. Likewise, the analysis of mice models of SMA
gave contradictory results. In a microarray-based study, late symp-
tomatic mice displayed widespread and tissue-speciﬁc changes in
the splicing pattern of a large number of mRNAs, no matter
whether they contained major or minor introns [37].
Furthermore, an RNA deep sequencing approach revealed neuron
speciﬁc mRNA dysregulations in presymptomatic SMA mice [41].
In contrast, other studies reported that changes in mRNA patterns
do not appear in pre-symptomatic SMA mice, suggesting that the
observed splicing effects are downstream effects of the loss of
SMN expression [38]. Hence, it is currently unclear whether
mis-splicing events observed in SMA animal models contribute
to the disease phenotype and whether similar events also con-
tribute to the disease in humans.
Apart from SMN’s role in RNP biogenesis, the protein has been
reported to fulﬁl additional functions, some of which are neuron
speciﬁc and related to mRNA metabolism [45–48]. At present, it
cannot be excluded that these functions, rather than the
above-mentioned role of SMN in splicing contribute to or even
cause the disease phenotype. Of potential relevance for the under-
standing of the SMA etiology is the role of SMN in the axonal trans-
port of certain mRNAs. SMN is present in axons of neurons,
including motor neurons affected in SMA. As a hallmark of motor
neurons is their very long axons (in humans they can be up to
one meter) it is tempting to speculate that reduced SMN levels
selectively affect motor neurons because this cell type critically
depends on mRNA transport along the axon.
3. Retinitis pigmentosa: defects in the splicing machinery
Whereas the analysis of the etiology of SMA revealed a link to
the production of spliceosomal U snRNPs and hence the
pre-mRNA processing spliceosome, some forms of the disease
retinitis pigmentosa (RP) are characterized by mutations in compo-
nents of the spliceosome itself. RP is a hereditary eye disease that
B. Linder et al. / FEBS Letters 589 (2015) 1598–1606 1601displays extreme genetic heterogeneity, with more than 60 under-
lying disease genes identiﬁed so far (RetNet, the Retinal
Information Network, www.sph.uth.edu/retnet/). Most protein
products of these genes are involved in various aspects of photore-
ceptor biology, including their development, their structure and
phototransduction itself. Despite this variety in disease genes,
the phenotype of isolated RP is very speciﬁc, affecting only the
retina. Therefore, it came as a surprise when it was discovered that
a mutation in PRPRF31, a core component of the spliceosome, was
found to cause RP [49]. Since then, however, several splicing fac-
tors were identiﬁed as RP disease genes, including 7 spliceosomal
proteins (PRPF31, PRPF16, PRPF8, PRPF6, PRPF4, PRPF3 and
SNRNP200) [49–56]. To date, it is estimated that more than 12%
of all cases of autosomal dominant RP (adRP) are caused by defects
in splicing factors [57].
All RP-linked splicing factors are core components of the
spliceosome. The formation of this multimeric complex begins
when the U1 snRNP subunit binds to the 50 splice-site of a
pre-mRNA (Fig. 3) (for review, see [25]). With the help of the
non-snRNP splicing factor U2AF, the U2 snRNP subunit is then
recruited to the branch point located close to the 30 splice-site of
the intron. Next, this so-called ‘‘A-complex’’ is joined by a
pre-assembled U4/U6.U5 tri-snRNP to form the B complex, which
upon a number of structural and compositional rearrangements
gives rise to the catalytically active complexes B* and C which cat-
alyze the ﬁrst and second transesteriﬁcation step of the splicing
reaction, respectively. During the activation of the spliceosome
and after the completion of the splicing reaction, the individual
snRNPs are released as monomers, from which they are recycled
and then can participate in another round of splicing [58]. While
the exact molecular functions of the RP-linked splicing factors dur-
ing the spliceosomal cycle are only beginning to be uncovered, itFig. 3. Spliceosomal proteins and retinitis pigmentosa. (left panel) The spliceosomal cycle
bind to the 50- and 30-splice sites of a pre-mRNA, respectively to give rise to the A comple
tri-snRNP, the RP-linked splicing factors enter the spliceosomal cycle. After the seque
transesteriﬁcation steps of the splicing reaction occur. Of note, the RP-linked splicing fa
SNRNP200 remain in the C complex (The BDU1 complex that arises after the loss of the U1
the tri-snRNP and the RP-linked spliceosomal proteins. The position of a subset of tri-snRN
[112]. Proteins encoded by RP disease genes are marked with a red star. The RP-linked sp
formation of the C-complex. Adapted from Häcker et al. [112] with permission from Mawas clear since their ﬁrst discovery in yeast that these factors are
crucial for spliceosome formation and intron removal [59]. This
creates the paradoxical situation that heterozygous mutations of
genes that are considered essential in all cells of the body evoke
a phenotype that is restricted to very few or even a single type of
cells.
Because a single gene product may have more than one biolog-
ical activity in the cell (‘‘protein moonlighting’’), it is difﬁcult to
exclude that an individual disease gene product, although consid-
ered a housekeeping gene, might have an additional, cell-type
speciﬁc function. However, unlike in the case of SMA, the defective
splicing factors in RP are all part of the same multimeric subcom-
plex of the spliceosome, the U4/U6.U5 tri-snRNP (Fig. 3), and it is
highly unlikely that the individual components all have an addi-
tional photoreceptor-speciﬁc function. Therefore, either the
tri-snRNP itself has a yet-to-be discovered function in photorecep-
tors, or the etiology of RP is directly linked to pre-mRNA splicing.
One hypothesis of how defects in pre-mRNA splicing can elicit a
cell-type speciﬁc defect is that there is a cell-type speciﬁc tran-
script that has a very high demand for splicing activity [60]. As
photoreceptors renew 10% of their rhodopsin containing discs in
a diurnal circadian rhythm and thus have to synthesize an enor-
mous amount of rhodopsin mRNA [61], the rhodopsin transcript
was considered a prime candidate for mediating this effect.
Indeed, it was demonstrated in HEK293 cells that splicing factor
defects inhibit the splicing of a transfected minigene construct
containing the short intron 3 of the human rhodopsin transcript
[62]. However, a number of reasons speak against mis-splicing of
this individual transcript as the disease-causing event: First, when
the full-length rhodopsin transcript was analyzed, no defects in the
splicing of this intron were found [63]. Second, splicing factor deﬁ-
ciency causes photoreceptor defects in zebraﬁsh [64], which do notassembles the spliceosome on its pre-mRNA substrate. First, the snRNPs U1 and U2
x. The tri-snRNP joins this complex to give rise to the B complex. Together with the
ntial loss of the snRNPs U1 and U4, the active C complex is formed and the two
ctors PRPF3, PRPF4, and PRPF31 are lost upon activation, while PRPF6, PRPF8 and
snRNP from the B-complex has been omitted for clarity). (right panel) Schematic of
P proteins is depicted on a structural model derived from cryo-electron-microscopy
licing factor PRPF16 is not part of the tri-snRNP but joins the spliceosome during the
cmillan Publishers Ltd.
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dence from a mouse model of splicing factor-linked RP suggests
that the primary defect lies in the retinal pigment epithelium
(RPE) rather than the photoreceptors themselves [66]. While it
must be noted that these animals display a late-onset phenotype
that might not completely resemble the situation in humans, it is
clear that their primary phenotype is in the RPE, which does not
express the rhodopsin transcript. Nevertheless, even without rho-
dopsin being the prime candidate for mediating the detrimental
effects of splicing factor mutations, the retina does seem to have
an extraordinarily high demand for splicing activity, as it has a
7-fold higher expression level of snRNAs than other tissues [60].
Accordingly, it has been proposed that the vulnerability of retinal
cells to splicing factor defects might stem from an unmet require-
ment for the production of sufﬁcient amounts of mature retinal
mRNAs [67].
It is important to note, however, that the shortfall of mature
mRNA is only one of the potential mechanisms for eliciting pho-
toreceptor cell death. For example, failure to remove an intron
might generate novel protein variants that are toxic for the cell.
Interestingly, retention of the rhodopsin intron 3 generates a
non-sense transcript that translates into a truncated protein with
a very efﬁcient peroxisomal localization sequence at its
C-terminus (B. Linder and U. Fischer, unpublished data).
Normally, the NMD surveillance pathway eliminates transcripts
affected by such premature termination events, but a small portion
of the highly expressed rhodopsin transcript might escape this
mechanism. Such non-sense transcripts are expected to be gener-
ated in large amounts and from a variety of genes if the general
splicing machinery is compromised. The effects of non-sense
mutations are well documented in human disease. NMD can mod-
ify the expressivity of such mutations and mask otherwise domi-
nant phenotypes [68]. One reason for the vulnerability of this
tissue to splicing defects might thus be an ‘‘overload’’ of the
NMD pathway. Testing whether the retina expresses increased
levels of the surveillance machinery to keep up with its high splic-
ing activity will help to gain insight into the extent at which NMD
modulates disease expressivity in splicing factor-linked RP.
Another mechanism by which defective tri-snRNPs might inﬂu-
ence the fate of the mRNAs produced is the deposition of the exon
junction complex on the spliced mRNA. This process is mediated
by the tri-snRNP associated protein CWC22 [69,70]. It has been
demonstrated that defects in CWC22 can lead to a spliced mRNA
that is devoid of EJCs [71,72]. Hence, if CWC22 is not properly
recruited to the spliceosome, this might alter the composition of
the resulting mRNP. This in turn can lead to a decreased translation
efﬁciency as well as to the evasion of NMD. Therefore, one might
envisage that tri-snRNP defects that interfere with CWC22 recruit-
ment could affect the expression of an mRNAwithout even altering
its splicing efﬁciency or splicing pattern. However, if EJC formation
is indeed affected in RP remains to be determined.
Finally, the tri-snRNP is not only important for constitutive
splicing, but also plays a role in the regulation of alternative splic-
ing events [73]. Because the joining of the tri-snRNP to
pre-mRNA-associated U1 and U2 snRNPs determines which 50
and 30 splice sites are used, this can give rise to mRNAs that either
include or skip speciﬁc exons. Interestingly, it has been found that
a number of alternative splicing events are affected in lym-
phoblasts derived from RP patients [60], suggesting that this might
be a key mechanism by which defective tri-snRNPs inﬂuence the
photoreceptor transcriptome.
Independent of the mechanism that ultimately links splicing
factor defects to photoreceptor cell death, it is clear that the
tri-snRNP particle plays a special role in the etiology of this disease,
as all RP-linked splicing factors reported so far are components of
this particle (except PRPF16, which joins independently of thetri-snRNP but directly binds to its components [74]). The fact that
the affected proteins are all part of the same multiprotein complex
opens up the possibility that defects in different tri-snRNP compo-
nents might act together to decrease the level of functional
tri-snRNPs below the threshold required in retinal cells. Such a
model has several implications for the genetics of RP. As mutant
alleles of different splicing factors would cause disease only in
combination, a large number of unaffected carriers and a high rate
of simplex cases is expected, exactly as it is observed for RP [75,76].
It might also explain why in some animal models the heterozygous
knockout of a tri-snRNP protein fails to evoke retinal defects
[77,78]. Thus a ‘‘single hit’’ might not be sufﬁcient to decrease
tri-snRNP function below the pathogenic threshold. Such a
mechanism has been reported for other protein complexes
involved in retinal degeneration such as the RDS/ROM complex
and the Bardet–Biedl-Syndrome (BBS) complex [79]. As a result,
in these cases the disease exhibits an oligogenic pattern of inheri-
tance [80]. Therefore, akin to what has been postulated for BBS
[81], the relatively large pool of unidentiﬁed RP disease genes is
likely to contain additional tri-snRNP splicing factors. The identiﬁ-
cation of novel RP mutations in splicing factors will hopefully not
only yield insights into the dynamic mechanisms of pre-mRNA
splicing, but also offer strategies for novel therapeutic approaches
in RP.4. X-linked syndromic mental retardation caused by mutations
in the UPF3b gene: regulation of brain development and
function by mRNA quality control
Whereas the diseases SMA and RP can be linked to pre-mRNA
processing, the third neuronal disease we want to discuss here pro-
vides a link to the mRNA quality control pathway termed
nonsense-mediated mRNA decay (NMD). This mRNA surveillance
mechanism ensures that transcripts containing premature transla-
tion termination codons (PTCs) are eliminated in eukaryotic cells
[82]. Thereby, NMD suppresses the synthesis of C-terminally trun-
cated proteins frommutated mRNAs and also regulates the expres-
sion of many genes, which represent endogenous NMD targets
[83]. Mechanistically, the presence of a PTC is detected during
translation termination. Termination at an inappropriate position,
as determined by either architecture of the mRNA or mRNP com-
position, leads to the assembly of a protein complex, consisting
of the proteins UPF1, UPF2 and UPF3 (Fig. 4A). This so-called
surveillance complex coordinates the recruitment of nucleases
and decapping complexes to the substrate mRNA in order to initi-
ate its degradation [84]. The three UPF proteins are conserved in all
eukaryotic organisms and act as central players of the NMD pro-
cess [85]. UPF3 interacts with the NMD factor UPF2 and with the
exon junction complex (EJC), a set of NMD-promoting factors,
which is assembled in the proximity of spliced-out introns on
mRNAs [86,87]. UPF2 functions as an adaptor protein that directly
binds to both UPF1 and UPF3 [85]. UPF1, an ATP-dependent RNA
helicase, interacts with mRNAs at a position downstream of the
termination codon and is regulated by its binding partner UPF2
[88].
In humans, UPF3 is expressed from two paralogous genes,
UPF3A and UPF3B, which share approximately 60% amino acid
identity and display a comparable domain architecture [89].
UPF3A and UPF3B are located on the long arm of chromosome 13
and on the long arm of chromosome X, respectively. While the
absence of UPF1 and UPF2 leads to an early embryonic lethality
in mice [90,91], the physiological role of the two mammalian
UPF3 genes is not well understood. Although both UPF3 proteins
are considered to serve redundant functions, functional differences
between them have been reported. UPF3B seems to be more active
Fig. 4. Simpliﬁed model of mammalian nonsense-mediated decay. Exon junction complexes (EJCs) are assembled upstream of splice junction in the nucleus and remain
bound to their binding site until the mRNA is translated in the cytoplasm. UPF3b interacts directly with core proteins of the EJC. (A) Transcripts with a normal termination
codon are translated into full-length proteins. During translation, EJCs are removed from the mRNA by ribosomes. (B) A premature termination codon (PTC) elicits NMDwhen
at least one EJC is located downstream. Translating ribosomes stop at the termination codon and a surveillance complex consisting of UPF1, UPF2 and UPF3 supports the
recognition of the EJC. Eventually, decay factors are recruited by UPF1 to degrade the substrate mRNA (not shown). (C) Schematic domain architecture of UPF3b. Domains
interacting with UPF2 and the EJC are depicted. Positions of disease-associated missense and nonsense/frameshift mutations are shown above and below the scheme,
respectively.
B. Linder et al. / FEBS Letters 589 (2015) 1598–1606 1603in triggering NMD and translation regulation and to bind more
efﬁciently to UPF2 than UPF3A [92,93]. Since the interaction with
UPF2 stabilizes the UPF3A protein, the presence of UPF3B destabi-
lizes UPF3A [93].
Mutations in the UPF3B gene have been identiﬁed in patients
with neuro-developmental disorders and intellectual disability
(ID), indicating a connection between the NMD pathway and
X-linked mental retardation (XLMR) [94]. Ten families carrying
UPF3B mutations have been analyzed and seven truncation muta-
tions and three missense mutations in the UPF3B gene have been
identiﬁed (Fig. 4B) [94–98]. It is very likely that truncation muta-
tions as well as missense mutations disturb UPF3B protein func-
tion, although they are located in different regions of UPF3B
(Fig. 4B). A broad range of clinical symptoms including autism,
schizophrenia and an abnormal long and thin face have been
observed in patients with UPF3B mutations [94]. This suggests that
UPF3B deﬁciency can lead to a variety of disease manifestationsand psychiatric disorders [95]. There was no consistent diagnosis
in patients with UPF3b mutations apart from ID. Therefore, highly
variable clinical expressivity of identical mutations has been sug-
gested [94–98]. Although the underlying mechanism for the clini-
cal variability is not known, the phenotype of patients with UPF3B
mutations is likely modulated by the functional redundancy of
UPF3B and UPF3A. Increased levels of UPF3A protein were
observed in patients’ cell lines, suggesting that UPF3A partially res-
cues NMD in the absence of functional UPF3B [93,99]. Moreover,
UPF3A levels inversely correlated with the severity of the neuro-
logical symptoms and may explain inter-individual differences
between patients from the same family [94,99]. Hence, UPF3A is
a potential modiﬁer of the clinical phenotype of UPF3B patients,
but the regulation of UPF3A protein levels remains elusive.
Recently, an association of heterozygous deletions of a genomic
region that include UPF2 with neuro-developmental disorders has
been reported [100]. In addition, a de novo missense mutation in
1604 B. Linder et al. / FEBS Letters 589 (2015) 1598–1606UPF2 has been identiﬁed in a patient with schizophrenia [101].
Similarly, copy number losses of genomic regions encompassing
UPF3A and copy number gains in genomic regions encompassing
genes involved in NMD were frequently found in patients with
ID [100]. Speciﬁcally, copy number gains of the NMD-speciﬁc
endonuclease SMG6 and two EJC factors, EIF4A3 and RNPS1, have
been described [100]. Patients with such copy number variations
of other NMD genes show a wide range of clinical symptoms, sim-
ilar to patients with UPF3B mutations. This supports the idea that
misregulation of NMD predisposes for a wide range of
neuro-developmental and psychiatric disorders [102,103].
How does NMD and in particular UPF3B contribute to normal
brain development and neuronal and synaptic homeostasis? This
question is very difﬁcult to answer and several different mecha-
nisms have been suggested. For example, the eIF4A3 protein, a
component of the NMD-activating EJC, has been shown to associate
with neuronal mRNA granules and dendritic mRNAs [104].
Furthermore, the central NMD factor UPF1 has been identiﬁed in
multi-protein complexes isolated from human postsynaptic den-
sity isolated from the neocortex [105]. Thus, NMD may regulate
the levels of mRNAs, which contribute to establish and maintain
synaptic functions.
One potential brain-speciﬁc substrate of NMD is the PTBP2
mRNA, which encodes a global regulator of neuronal-speciﬁc splic-
ing programs [106,107]. The splicing of PTBP2 is regulated by its
homolog PTBP1 in non-neuronal cells and neural progenitor cells.
In these cells the presence of PTBP1 leads to skipping of exon 10
of PTBP2. This isoform of PTBP2 contains a frameshift, which leads
to its degradation by NMD. However, when neural progenitor cells
differentiate into immature neurons, the expression levels of
PTBP1 strongly decrease. This results in inclusion of exon 10 into
the PTBP2 mRNA and the biosynthesis of functional PTBP2 protein,
which controls splicing events involved in the initiation of neu-
ronal maturation [108]. Another neuron-speciﬁc NMD substrate
is the Arc mRNA, which is one of the most abundant transcripts
in dendrites and up-regulated upon synaptic activation. Arc pro-
tein is required for maintenance of long-term potentiation. The
down-regulation of eIF4A3 in cultured neurons leads to an
increased abundance of the Arc protein, which in turn increased
excitatory synaptic strength [104]. Since this observation is in con-
ﬂict with data showing that the genetic knockout of Arc increase
both synaptic strength and Arc overexpression in cultured hip-
pocampal neurons led to a defect in synaptic scaling [109] future
work will be required to solve this apparent discrepancy.
The important function of NMD factors during brain develop-
ment is underscored by their strict regulation. Notably,
neuron-speciﬁc regulation of NMD is mediated by miR-128, which
targets UPF1 and the EJC component MLN51. While undifferenti-
ated P19 cells express only small amounts of miR-128, they dra-
matically upregulate mature miR-128 transcripts to repress NMD
when differentiation into neuron-like cells is induced [110].
Furthermore, the expression of several NMD factors is regulated
by a negative feedback loop, which has been suggested to
ﬁne-tune the activity of NMD in a cell type-dependent manner
[111].
Based on the ﬁndings summarized above it is likely that NMD
plays an important role in the central nervous system. Therefore,
mutations and copy number variations that interfere with NMD
activity and alter neuronal gene expression contribute to human
neurodevelopmental disorders.
5. Conclusions and perspectives
The above diseases represent just a small selection of a growing
number of disorders that are caused by mutations in factors thatact on, or associate with, mRNA. An interesting common aspect is
that the underlying genetic defects appear to affect factors
involved primarily in housekeeping, rather than cell type speciﬁc
functions. This is probably best underlined in the case of RP, where
several components of the tri-snRNP are affected, thereby making
it unlikely that the tissue-speciﬁc phenotype is caused by addi-
tional, cell-type speciﬁc functions of the mutant proteins.
However, also in the case of SMA and XLMR there is evidence that
it is the defective housekeeping function of the affected protein
that causes the neuron-speciﬁc phenotype rather than an addi-
tional, cell-type speciﬁc function: For mutations in SMN, it has
been shown that the end-product of the snRNP biogenesis pathway
can rescue the neuronal phenotype in zebraﬁsh [34]. In the case of
NMD, it was found that – similar to the situation found in RP – sev-
eral components of this pathway are linked to neuronal disease. In
addition, while the main function of NMD is the surveillance of the
transcriptome for erratic PTCs, it has been demonstrated that the
same decay pathway is responsible for the post-transcriptional
regulation of important neuronal mRNAs, so that it is unlikely that
an additional, non-NMD function of these proteins is responsible
for the neuron-speciﬁc phenotype. It should be mentioned, how-
ever, that at present for none of the disease-related factors dis-
cussed here, a tissue speciﬁc activity, in addition to their
housekeeping functions can be excluded that contributes to the
etiology.
Why speciﬁc cells are especially vulnerable to defects in general
mRNA metabolism is therefore a key question that concerns the
etiology of SMA, RP and XLMR alike. One explanation for this para-
doxical situation might be that the affected pathways in SMA, RP
and X-linked syndromic mental retardation ensure the catalytic
conversion of a large variety of different (mRNA) substrates by
splicing and NMD, respectively. Considering that there are ‘‘good’’
substrates (i.e. those that are efﬁciently recognized and converted)
and ‘‘weak’’ ones, it is tempting to speculate that mutations in gen-
eral mRNA processing factors do not affect all substrates alike.
Such a scenario could indeed present a general explanation for
how defects in housekeeping pathways convert into a tissue speci-
ﬁc phenotype. The systematic analysis of mRNAs by current
high-throughput technologies should enable the identiﬁcation of
the affected transcripts and allow detailed insight into the etiolo-
gies of this type of diseases.
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